Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre

BACKGROUND: Regorafenib is a multi-kinase inhibitor approved as third line treatment for metastatic GIST. Dose limiting toxicities are frequently seen and many patients require dose reductions. This study aimed to evaluate regorafenib toxicities and their management in a real-world GIST population....

Descripción completa

Detalles Bibliográficos
Autores principales: Chamberlain, Florence, Farag, Sheima, Williams-Sharkey, Constance, Collingwood, Cecilia, Chen, Lucia, Mansukhani, Sonia, Engelmann, Bodil, Al-Muderis, Omar, Chauhan, Dharmisha, Thway, Khin, Fisher, Cyril, Jones, Robin L., Gennatas, Spyridon, Benson, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942401/
https://www.ncbi.nlm.nih.gov/pubmed/31911828
http://dx.doi.org/10.1186/s13569-019-0123-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942401/
https://www.ncbi.nlm.nih.gov/pubmed/31911828
http://dx.doi.org/10.1186/s13569-019-0123-4

Ejemplares similares